Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | UNK | — | OT |
second dose was supposed to be given on the 7th day, but there was a delay, and the patient was administered of their second dose 2 weeks after their supposed schedule with no reported adverse evenf; Initial information received on 21-Jul-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 23 years old and unknown gender patient who had second dose of Rabies (Hdc) Vaccine [Imovax Rabies] was supposed to be given on the 7th day, but there was a delay, and the patient was administered of their second dose 2 weeks after their supposed schedule with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of suspect Rabies (Hdc) Vaccine, Powder and solvent for suspension for injection (lot number, expiry date and strength not reported) via unknown route in unknown administration site for Immunisation and second dose was supposed to be given on the 7th day, but there was a delay, and the patient was administered of their second dose 2 weeks after their supposed schedule with no reported adverse event (inappropriate schedule of product administration) (latency same day). Information on the batch number was requested corresponding to the one at time of event occurrence Reportedly, a patient was supposed to receive a 3-dose series of IMOVAX. Their second dose was supposed to be given on the 7th day, but there was a delay, and the patient was administered of their second dose 2 weeks after their supposed schedule. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.